BTG3 and systemic lupus erythematosus: With the advent of multi-analyte arrays with algorithmic analysis (MAAA) as an approach to PH (2, 3, 66) the value of these autoantibodies may be discovered when they are combined and permutated with other biomarkers, and hence fill seronegative gaps such as in antinuclear antibody (ANA)-negative SLE (67, 68) and other systemic autoimmune rheumatic diseases (SARD) (69–73).